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Abstract 1 
Background: Bleomycin is an integral part of combination chemotherapy in germ cell tumours. 2 
Pulmonary toxicity often necessitates drug cessation and death occurs in 1-2% of patients. A 3 
continuous infusion of bleomycin might reduce lung toxicity when compared to the 4 
conventional weekly boluses given as part of standard BEP chemotherapy. 5 
Patients and Methods: A phase 3 randomised trial was conducted. Two hundred and twelve 6 
men with IGCCCG good prognosis metastatic germ cell tumours were randomized in a 1:1 7 
fashion. They were stratified for age, smoking history and renal function. Patients received 8 
either conventional BEP with weekly bleomycin (30000 units /week IV bolus) or as a 90000 unit 9 
infusion on day 1 over 72 hours. The primary endpoint was CT assessed lung toxicity, secondary 10 
endpoints included PFS, changes in lung function testing and quality of life. Repeated measures 11 
mixed effects model was used to analyse the data. 12 
Results: CT assessed lung toxicity for the infusional and conventional arm patients were respectively 13 
80% versus 62% at the end of treatment and 54% versus 51% at one year post treatment. There was no 14 
significant difference between the two arms for CT assessed lung toxicity (estimated regression 15 
coefficient (difference) =1.4, P=0.9, 95% CI:-0.36, 3.16). Older patients had higher toxicity 16 
(coefficient=4.81, 95% CI: 3.04, 6.58). Lung toxicity increased after 1 cycle and peaked at end of 17 
treatment (P≤0.002) and then declined. Lung function testing failed to show any differences 18 
between the two arms, and did not predict for subsequent lung damage. The median follow-up 19 
was 2.5 years. Two-year PFS rate (infusional arm= 93% versus conventional arm=94%; hazard 20 
ratio =0.91, 95% CI: 0.33, 2.52) was not significantly different. Cough (P=0.002) but not 21 
shortness of breath (P≥0.09) was associated with bleomycin toxicity.  22 
Conclusions: Infusional bleomycin has no advantage over standard administration. It supports 23 
abandoning routine pulmonary function testing, instead the presence of cough should be 24 
sought and the early use of CT scanning of the chest to evaluate potential lung toxicity is 25 
preferred. 26 
Keywords: germ cell tumour, bleomycin, infusion, lung  27 
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Introduction 28 
Most patients with IGCCCG good prognosis metastatic germ cell tumours are cured with 3 29 
cycles of cisplatin, etoposide and bleomycin (BEP). Randomised studies have confirmed 30 
cisplatin100mg/m2, etoposide 500mg/m2 and bleomycin 90,000 units per cycle to be optimal 31 
[1, 2]. The cisplatin and etoposide may be given over 3 or 5 days [2] and reductions in the 32 
dosage of bleomycin or etoposide are associated with poorer overall survival [1, 3]. Bleomycin 33 
has long been known to cause unpredictable and occasionally fatal lung toxicity. Prior poor lung 34 
function, a smoking history, and impaired renal function may predispose to an increased 35 
likelihood of toxicity [4]. Retrospective reports suggest that the damage caused by bleomycin 36 
be related to the peak levels of the drug which may be avoided by giving the drug as a 37 
continuous infusion [5]. In vivo experiments in animal models support this hypothesis [6]. 38 
In a patient group with a good outcome, optimisation of bleomycin may be expected to 39 
improve efficacy and reduce toxicity. As the value of pulmonary function testing in this setting 40 
has been controversial [7] we wished to see whether pre- treatment pulmonary function 41 
testing could identify an at-risk population for development of lung toxicity and whether 42 
changes during treatment correlated with the development of CT scan changes. We also wished 43 
to determine whether any symptoms associated with the development of bleomycin induced 44 
lung injury e.g. shortness of breath, cough, and chest discomfort correlated with CT changes. 45 
We therefore performed a randomised trial. 46 
 47 
Patients and Methods 48 
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Eligible patients were males over 16years old with IGCCCG good prognosis disease (testicular 49 
germ cell tumours with metastases but no non-pulmonary visceral sites with tumour markers 50 
not exceeding the following AFP 1000ng/ml, hCG, 5000 iU/ml, LDH 1.5x the upper limit of 51 
normal).  52 
All patients were staged using CT scanning. The pulmonary parenchyma was assessed using 53 
conventional lung settings rather than dedicated high resolution CT of the chest. Patients were 54 
required to have adequate renal function (calculated or measured glomerular filtration rate of > 55 
50ml/min). Patients were randomised to receive 3 cycles of 3 day BEP (cisplatin 50mg/m2 on 56 
day 1 and 2, etoposide 166mg/m2 day 1, 2 and 3) and either conventional bleomycin 30,000 57 
units per week on days 1, 8 and 15 as a 30min intravenous infusion (conventional arm) or a 58 
protracted infusion (90,000 units as a continuous intravenous infusion over 3 days on days 1, 2 59 
and 3 of each cycle (infusional arm). Routine use of growth factors was not permitted.. A 60 
conventional chest CT, quality of life, and pulmonary function tests were performed 61 
immediately prior to the second cycle, at the end of treatment (9 weeks after chemotherapy 62 
started), 1 year and 2 years after treatment.  63 
Quality of life assessments used the EORTC QLQC-30 questionnaire with the addition of LC 17 64 
(originally developed for lung cancer, it was used to look for specific symptoms attributable to 65 
lung toxicity) [8].  66 
The primary end point of the study was the development of CT assessed lung toxicity 67 
attributable to bleomycin. The validated endpoint CT changes were selected, as they, rather 68 
than changes in lung function correlate best with long term pulmonary damage [4, 9, 10].  The 69 
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secondary endpoints were progression-free survival, overall survival, changes in pulmonary 70 
function testing, and quality of life. Pulmonary function tests included an assessment of FEV1, 71 
FVC, TlCO and KCO. 72 
Patients were required to give written informed consent. The trial had formal ethical approval 73 
(trial reg MREC 3/3/029). 74 
 75 
CT review 76 
All the CT scans were anonymised, the reporting radiologist was blinded to treatment allocation 77 
and all scans viewed by a single radiologist.  The scans were reported as follows. As this was a 78 
multicentre trial, scan acquisition varied according to institution, but in all cases, slice thickness 79 
was no more than 2.5mm. Where dedicated lungs settings were not provided, a standard edge 80 
algorithm was applied. Each lung field was split into an anterior and posterior section (4 in all- 81 
right anterior, right posterior, left anterior and left posterior). The degree of CT assessed lung 82 
toxicity was graded between 0-3. Grade 1 changes represented subtle fine sub-pleural linear 83 
opacity, grade 2 changes – more pronounced than grade 1 but with no coalescence or 84 
consolidation. Grade 3 represented more diffuse changes with coalescence [11].  The number 85 
or total sections with subpleural changes for each scan examined was noted allowing a 86 
percentage of sections with involved  changes to be derived, as well as the proportion of grade 87 
2 and 3 changes. The results were summarised in the following format – the percentage of 88 
sections showing any damage, the number of sections showing individually grade1, 2 or 3 89 
damage. This was carried out at baseline, day 21, end of treatment and 1 and 2 years post 90 
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treatment. In some patients changes were present prior to chemotherapy – these were termed 91 
baseline changes, their subsequent presence post chemotherapy were therefore not 92 
attributable to bleomycin. 93 
 94 
Statistics 95 
A previous retrospective review of the toxicity encountered when bleomycin was administered 96 
as a continuous infusion had suggested a substantial reduction in bleomycin induced changes (a 97 
difference of 44%). It was felt to be worthwhile even if the reduction in toxicity were around 98 
15%. Therefore a reduction in toxicity from 27% (expected) to 11% required a total of 210 99 
patients at the 5% level of significance with 80% power based on a 2-sided test.   100 
Randomisation, following 1:1 allocation, was stratified for smoking (smoker vs non-smoker), 101 
renal dysfunction (> 80ml/min or ≤80ml/min as calculated by Cockroft and Gault) and age (<30 102 
vs ≥30 years) as all these factors have been associated with an increased risk of bleomycin 103 
induced lung toxicity [4, 12].  104 
To determine the statistical significance of the association between categorical and continuous 105 
outcome variables, the Chi-square and Independent samples T-test were used as appropriate. 106 
Repeated measures mixed effects models were used to model CT proven lung toxicity as a 107 
function of the predictor variables accounting for both fixed effects (stratification factors) and 108 
random effect(patient ID). Nonparametric testing for trend was carried out to observe for 109 
trends in toxicity grading with time. Pearson’s correlation coefficients were used to assess 110 
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correlation between lung function variables and lung toxicity at each time point and then linear 111 
regression was used for prediction. Association between quality of life (symptoms) and change 112 
of lung toxicity (end of treatment - baseline) was studied using two-sample t-test. 113 
 114 
Results  115 
Two hundred and twelve patients from 13 sites were randomised (105 in the infusional arm and 116 
107 in the conventional arm), see CONSORT diagram in S1. Table 1 confirms the validity of 117 
randomization with the two groups well balanced in terms of baseline characteristics. Thirty-118 
five percent of patients were smokers, 5% had an estimated GFR of < 80ml/min and 53% were 119 
over the age of 30. The median follow-up was 2.3 years.  120 
The proportion of patients with CT detected lung toxicity (any, grade ≥2, grade 3) respectively increased 121 
from baseline (12.2%, 0%, 0%) to day 21 (29.5%, 2%, 0%) and end of treatment (705%, 34.5%, 5.1%) but 122 
improved at 1 year post treatment (52.4%, 4.2%, 0.6%) and 2 years post treatment (47.9%, 2.6%, 0.9%). 123 
There was a significant trend for increasing CT defined toxicity after 1 cycle, which peaked at 124 
the end of treatment (P≤0.002). 125 
Thirty percent of patients (n=37) had CT assessed grade 1 toxicity by day 21 and 35% of them 126 
increased to grade≥2 toxicity by the end of the treatment. Eighty four (68%) patients showed no 127 
evidence of lung toxicity at day 21 but 27% of them went on to develop grade≥2 lung toxicity at 128 
the end of treatment.   129 
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Those patients with smaller body surface areas (< median) did not have significantly higher 130 
toxicity (small BSA: 38% vs higher BSA: 34%, P=0.18) at the end of treatment despite the fact 131 
that bleomycin dosing was fixed independently of body size. 132 
 133 
Treatment comparison: 134 
Table 2 shows that toxicity in the infusional arm was generally higher than the conventional arm 135 
and it was significantly higher at the end of treatment (80% vs. 62%, P=0.01). 136 
Repeated measures mixed effects analysis, Table 3, shows that there was no significant 137 
difference (CI includes zero) in percentage of grade ≥1 toxicity between the two arms 138 
(estimated coefficient=1.4; 95% CI: -0.36, 3.16). It confirms that a significantly higher level of 139 
grade ≥2 toxicity in the infusion arm (0.92; 0.22, 1.62) mainly at the end of treatment. Baseline 140 
toxicity was significant (1 unit increase gave the percentage of grade ≥2 toxicity decrease by a 141 
factor of 0.16). Of the stratified factors only age was statistically significant. Patients older than 142 
30 had on an average 4.8 percentage point higher grade ≥1 toxicity but 0.84 percentage point 143 
lower grade ≥2 toxicity. Smoking was not associated with baseline damage (P = 0.5), nor was it 144 
related to the severity and frequency of subsequent bleomycin toxicity (Table 3). The total 145 
doses of bleomycin was the same in both groups. 146 
Two-year PFS rate (infusional arm= 92.5% versus conventional arm=94.1%; hazard ratio =0.91, 147 
95% CI 0.33 to 2.52) was not significantly different.  148 
 149 
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Lung function and CT assessed toxicity: 150 
There was no relationship between pre-existing lung function and subsequent CT assessed 151 
toxicity (see Table 4). Pulmonary function declined during treatment and then recovered 1 year 152 
post therapy (Figure S2). Table 4 shows that decreased lung function was weakly correlated (r≈-153 
0.30) with increased toxicity only at the end of treatment (P <0.05), especially based on DLCO 154 
(kco). Pre-treatment lung function did not predict subsequent development of pulmonary 155 
toxicity (all CIs include 0); (Table S1).  156 
 157 
Quality of Life (see Table 5) 158 
The quality of life data showed that the development of a dry cough (P=0.002) rather than 159 
shortness of breath (P≥0.09) or chest tightness (P=0.18) was the only symptom significantly 160 
associated with the development of CT assessed lung toxicity. Shortness of breath showed a 161 
positive association with the development of CT assessed lung toxicity but was not significant 162 
(P=0.09).   163 
 164 
Discussion 165 
A continuous infusion of of bleomycin over 72 hours was unable to reduce the likelihood of 166 
developing pulmonary toxicity compared to conventional administration. There was 167 
significantly higher level of grade ≥2 toxicity in patients in the infusion arm, refuting the above 168 
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hypothesis. Nevertheless this study has expanded our knowledge as to the timing of 169 
development of lung toxicity and the natural history of its resolution.  170 
There was no suggestion that efficacy was increased by this approach despite animal models 171 
suggesting otherwise [6]. Supporting this conclusion, an in vivo study based on hetero-172 
transplanted testicular cancer cell lines found no significant difference in anti-tumour activity or 173 
toxicity on histological examnination between continuous or bolus application of bleomycin 174 
where the same cumulative doses were compared [11]. 175 
Pulmonary toxicity from bleomycin may be related to peak levels and one weakness of this 176 
study was failure to measure these – it is possible that the infusion produced higher levels than 177 
anticipated and that a more prolonged infusion might have reduced toxicity. 178 
This was a pragmatic study – high resolution CT scanning was not used to assess pulmonary 179 
toxicity on the basis that we were not looking for a test to be more sensitive but wanted to 180 
assess clinically more relevant changes. It could be argued that the varying scan protocols and 181 
acquisition parameters could have obscured significant differences, but the within-institution 182 
randomisation ensured that such bias was minimised. Similarly, subtle changes attributable to 183 
bleomycin could have been obscured by normal hypostatic changes, since prone scans were not 184 
routinely acquired, but this would be expected to affect subjects in both arms equally and the 185 
fact that serial scans were obtained in each patient minimised the likelihood of changes being 186 
missed or misinterpreted. Whilst intra-observer variability was controlled for by – re-reporting 187 
of blinded scans - a weakness of having only one radiologist reporting all the scans was that the 188 
potential role of inter-observational error could not be assessed.  189 
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The finding of changes, progressing until the end of treatment and then regressing, offers an 190 
opportunity for using early changes as a warning for more severe damage if bleomycin is 191 
continued. A recent study confirmed a similar pattern of change in lung damage as seen in TE3 192 
with most of the changes in lung function reversing within 1 year of treatment[13]. They 193 
however used changes in diffusion capacity to reduce or omit bleomycin   which they felt did 194 
not reduce survival. Their study differed in that it included poor and intermediate prognosis 195 
patients who would have received 4 cycles of bleomycin. This may be important as many of the 196 
factors thought to be associated with subsequent pulmonary toxicity were not borne out in our 197 
study. Neither baseline pulmonary, nor smoking history, nor renal function predicted toxicity, 198 
however In the case of renal function, most (92%) had an estimated glomerular filtration rate  199 
of > 80ml/ min, so although no association was noted it might simply suggest that only 200 
significantly impaired renal function increased bleomycin toxicity.  201 
 202 
Bleomycin lung toxicity remains unpredictable and can be fatal which can lead to dropping 203 
bleomycin to avoid risk. For 3 cycles of cisplatin and etoposide the absence of bleomycin was 204 
associated with a poorer survival [14]. It is unclear whether dropping bleomycin can be 205 
compensated for by the addition of a 4th cycle of cisplatin and etoposide. One study – 206 
underpowered to show a survival difference showed a 5% higher event rate in patients 207 
randomized to 4 cycles of cisplatin and etoposide [15].  208 
 209 
Pulmonary function testing was not useful to identify patients at risk of developing lung toxicity. 210 
It was stipulated in the study that no reductions in bleomycin dosage for asymptomatic changes 211 
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in pulmonary function testing should be made. This is not the first time that the value of 212 
pulmonary function testing has been questioned [16]. This argues for the abandonment of 213 
routine pulmonary function testing, which may avoid patients having their bleomycin omitted. 214 
 In our study, early CT scanning after 1 cycle of treatment, rather than pulmonary function 215 
testing or smoking history, was best able to identify patients at risk of subsequent lung toxicity.  216 
 217 
The symptom assessment questionnaire showed that cough rather than shortness of breath 218 
was the most important symptom to assess before administration of bleomycin and if this were 219 
noted in the absence of another cause, an early CT of the chest might be performed prior to 220 
further administration of bleomycin to establish if pulmonary toxicity had occurred.  221 
The number of treatment failures in each arm (6%) was less than seen in previous randomised 222 
studies in this population [1, 2] despite the fact that the median age group was higher (32 223 
years) than in comparable studies. The low level of treatment delays and drug omissions may 224 
have been responsible for this. It is important to point out that the overall prevalence of 225 
bleomycin induced lung damage was relatively low due to the fact that the study only included 226 
patients with good prognosis disease. In patients with more pulmonary disease where the total 227 
doses of bleomycin would be greater, risks would likely be higher. In a review by Sullivan et al 228 
[4] of patients treated, age, dose (> 300, 000 units) and renal dysfunction were associated with 229 
increased risk of damage. 230 
 231 
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Conclusions: 232 
Bleomycin induced lung damage in patients with good prognosis germ cell tumours occurs 233 
independently of the method of delivery. The study supports the abandoning of routine 234 
pulmonary function testing both to identify patients at risk or during treatment as a means of 235 
detecting deterioration in pulmonary function. Instead, symptoms, especially cough, leading to 236 
the early use of CT is preferred. A history of smoking may not be a reason to withhold 237 
bleomycin. Whether these findings extend to patients with more advanced disease remains 238 
undetermined.  239 
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Table 1. Baseline characteristics of study patients 
Baseline 
characteristics 
Infusional arm  
(N= 105) 
Conventional (Bolus) 
arm (N= 107) 
n % n % 
Baseline toxicity 
(mean (SD))* 0.89 (4.5) 0.78 (2.5) 
Age (years)         
  <=30 49 46.7 51 47.7 
  >30 56 53.3 56 52.3 
Age (years) 
(median (IQR)) 31.5 (26.5, 36.0) 31.5 (24.8, 39.1) 
Follow-up (years) 
(median (IQR)) 2.3  (1.9, 3.7) 2.3 (2.1, 3.5) 
Smoking status         
  Non-smoker 67 63.8 71 66.4 
  Smoker 38 36.2 36 33.6 
Creatinine 
clearance         
  <=80 ml/min 7 6.7 4 3.7 
  >80 ml/min 98 93.3 103 96.3 
* % of grade ≥1 toxicity at baseline (i.e. changes present prior to 
treatment) 
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Table 2. Percentage of patients with various level of CT assessed lung toxicity 
 Baseline P Day 21 P End of treatment P 1-year p 2-year P 
 IA1 CA2  IA CA  IA CA  IA CA  IA CA  
Any grade 9.5 15.0 0.34 31.5 27.3 0.71 79.8 62.0 0.01 54.3 50.6 0.65 50.9 45.2 0.58 
Grade ≥2 0 0 - 4.0 0 0.25 44.7 25.0 0.01 3.7 4.6 1.00 3.6 1.6 0.60 
Grade 3 0 0 - 0 0 - 8.2 2.2 0.09 1.2 0 0.48 1.8 0 0.47 
1IA: Infusional Arm. 2CA: Conventional Arm.  
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Table 3. Repeated measures mixed effects models for levels of CT assessed lung toxicity 
  
% of Grade ≥1  toxicity % of Grade ≥2 toxicity 
% of Grade 3                                      
toxicity 
Estimated coefficient 
(Difference) 95% CI 
Estimated  
coefficient 
(Difference) 95% CI 
Estimated  
coefficient 
(Difference) 95% CI 
Treatment             
  Conventional arm ref 
 
ref 
 
ref 
 
  Infusional arm 1.4 -0.36, 3.16 0.92 0.22, 1.62 0.05 -0.11, 0.22 
Baseline toxicity 0.67 0.40, 0.94 0.16 0.04, 0.28 0.002 -0.03, 0.03 
Age (years)             
  <=30 ref 
 
ref 
 
ref 
 
  >30 4.81 3.04, 6.58 0.84 0.14, 1.55 0.14 -0.03, 0.30 
Smoking status             
  Non-smoker ref 
 
ref 
 
ref 
 
  Smoker 0.49 -1.36, 2.34 0.06 -0.68, 0.79 0.11 -0.06, 0.28 
Creatinine clearance             
  <=80 ml/min ref 
 
ref 
 
ref 
 
  >80 ml/min -0.79 -5.26, 3.68 0.15 -1.58, 1.88 -0.03 -0.44, 0.38 
CT assessed toxicity              
  Day 21 ref 
 
ref 
 
ref 
 
  End of treatment 7.28 5.50, 9.06 2.25 1.55, 2.96 0.17 -0.002, 0.33 
  1 year post treatment 2.18 0.38, 3.98 0.08 -0.63, 0.79 -0.01 -0.18, 0.16 
  2 year post treatment 2.14 0.14, 4.14 - 
 
- 
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Table 4. Correlation between lung function and lung toxicity  
Lung function test 
Grade ≥1 lung toxicity   
Baseline End of treatment One year post treatment 
    r P r P r P 
Baseline 
fvc 0.03 0.7 -0.03 0.7 -0.02 0.8 
fev1 0.01 0.9 -0.13 0.1 -0.09 0.3 
tlc 0.03 0.8 0.02 0.8 0.02 0.8 
tlco -0.07 0.5 -0.08 0.3 -0.07 0.4 
kco -0.07 0.4 -0.08 0.3 -0.05 0.5 
End of 
treatment 
fvc 
- - 
-0.32 <0.001 -0.26 0.003 
fev1 -0.36 <0.001 -0.27 0.003 
tlc -0.19 0.06 -0.22 0.03 
tlco -0.35 <0.001 -0.26 0.004 
kco -0.2 0.02 -0.09 0.34 
One year 
post 
treatment 
fvc 
- - - - 
-0.17 0.11 
fev1 -0.17 0.11 
tlc -0.07 0.6 
tlco -0.21 0.04 
kco -0.04 0.7 
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Supplementary Table S1. Simple linear regression analysis results for association between 
pre-treatment lung function and end of treatment toxicity 
 End of treatment toxicity 
 % of Grade ≥1 toxicity % of Grade ≥2 toxicity % of Grade 3 toxicity 
Pre-treatment 
lung function 
Regression 
coefficient 
95% CI Regression 
coefficient  
95% CI Regression 
coefficient  
95% CI 
Baseline fvc -0.45 -3.08, 2.18 -0.62 -1.84, 0.61 -0.01 -0.16, 0.23 
Baseline fev1 -2.58 -5.80, 0.63 -1.1 -2.61, 0.40 0.12 -0.18, 0.41 
Baseline tlc 0.28 -2.14, 2.70 -0.17 -1.30, 0.95 -0.05 -0.31, 0.20 
Baseline tlco -0.61 -1.79, 0.58 -0.46 -1.02, 0.09 0.01 -0.10, 0.13 
Baseline kco -3.93 -11.94, 4.07 -1.74 -5.51, 2.03 0.02 -0.74, 0.78 
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Table 5. Association between symptoms and change of lung toxicity (end of treatment - 
baseline) 
Symptoms 
Mean Grade ≥1 % lung toxicity Mean Grade ≥2 % lung toxicity 
Better or no 
change 
compared to 
baseline 
Worse P Better or no 
change 
Worse P 
Cough 8.3 17.3 0.001 1.8 5.9 0.002 
Cough up mucus 10.4 13.3 0.33 3.0 3.4 0.8 
Cough up blood - - - - - - 
Tightness in chest 10.7 12.2 0.6 2.6 4.5 0.18 
SOB at rest 12.0 7.2 0.16 3.7 0.7 0.09 
SOB on walking 11.1 11.4 0.9 3.2 2.9 0.8 
SOB on climbing 
stairs 10.4 12.9 0.36 3.0 3.4 0.8 
 
  
22 
 
 
Supplementary Figure S1: Consort diagram showing study population 
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Supplementary Figure S2. Trend in toxicity based on lung function tests by arm 
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